title: PROX1 is a predictor of survival for gliomas WHO grade II.
abstract: BACKGROUND
  The clinical course of World Health Organisation grade II gliomas remains variable and their time point of transformation into a more malignant phenotype is unpredictable. Identification of biological markers that can predict prognosis in individual patients is of great clinical value. PROX1 is a transcription factor that has a critical role in the development of various organs. PROX1 has been ascribed both oncogenic and tumour suppressive functions in human cancers. We have recently shown that PROX1 may act as a diagnostic marker for high-grade gliomas. The aim of this study was to address the prognostic value of PROX1 in grade II gliomas.
  
  
  METHODS
  A total of 116 samples were evaluated for the presence of PROX1 protein. The number of immunopositive cells was used as a variable in survival analysis, together with established prognostic factors for this patient group.
  
  
  RESULTS
  Higher PROX1 protein was associated with poor outcome. In the multivariate analysis, PROX1 was identified as an independent factor for survival (P=0.024), together with the presence of mutated isocitrate dehydrogenase 1 R132H protein, and with combined losses of chromosomal arms 1p/19q in oligodendrocytic tumours.
  
  
  CONCLUSIONS
  PROX1 is a novel predictor of survival for grade II gliomas.
authors.affiliation: Department of Oncology-Pathology, Karolinska Institutet, CCK R8:05, Karolinska University Hospital, S-17176 Stockholm, Sweden.
authors.forename: T
authors.initials: T
authors.lastname: Elsir
authors.forename: M
authors.initials: M
authors.lastname: Qu
authors.forename: S G
authors.initials: SG
authors.lastname: Berntsson
authors.forename: A
authors.initials: A
authors.lastname: Orrego
authors.forename: T
authors.initials: T
authors.lastname: Olofsson
authors.forename: M S
authors.initials: MS
authors.lastname: Lindström
authors.forename: M
authors.initials: M
authors.lastname: Nistér
authors.forename: A
authors.initials: A
authors.lastname: von Deimling
authors.forename: C
authors.initials: C
authors.lastname: Hartmann
authors.forename: D
authors.initials: D
authors.lastname: Ribom
authors.forename: A
authors.initials: A
authors.lastname: Smits
mesh_terms: D000328:Adult; D014408:Biomarkers, Tumor / Q000032:analysis; D001932:Brain Neoplasms / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D005260:Female; D005910:Glioma / Q000175:diagnosis* / Q000401:mortality / Q000473:pathology; D018398:Homeodomain Proteins / Q000378:metabolism*; D006801:Humans; D007521:Isocitrate Dehydrogenase / Q000032:analysis* / Q000235:genetics*; D019656:Loss of Heterozygosity; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011379:Prognosis; D016019:Survival Analysis; D025521:Tumor Suppressor Proteins / Q000378:metabolism*; D000098551:Prospero-Related Homeobox 1 Protein
chemical_list: D014408:Biomarkers, Tumor; D018398:Homeodomain Proteins; D025521:Tumor Suppressor Proteins; D000098551:Prospero-Related Homeobox 1 Protein; D007521:Isocitrate Dehydrogenase; C543588:IDH1 protein, human